Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
Silvia Rota, Simon S. Skene, Alexa King, Vincenzo Libri et al.
Citations
94 citations
Journal
The Lancet
Topics
Parkinson's Disease Mechanisms and Treatments
Field-Weighted Citation Impact (FWCI)
130.59
article
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
Silvia Rota, Simon S. Skene, Alexa King, Vincenzo Libri, Jacqueline Kerr, Nirosen Vijiaratnam, Monty Silverdale, Jessica Welch, Thomas Foltynie, К. Ray Chaudhuri, Patricia Limousin, Edwin Jabbari, Dilan Athauda, Jemma Inches, Camille Carroll, Rachel Gibson, Nigel H. Greig, Grace Auld, Christine Girges, John Dickson, Kashfia Chowdhury, Kevin Power, Gordon W. Duncan, Helen Matthews, Sabina Melander, Bethan Blackledge, Lucia Batzu, Huw R. Morris, Steve Hibbert, Rachel McComish, Yazhou Li, Sonia Gandhi, Alan Wong, Abigail Patrick, Jessica Whiston, Sarah Gallen
article en
94 citations
Abstract
No abstract available for this paper.
Publication Tag
The LancetVol. 405(10479)
Institutions
Queen Mary University of London (GB), Royal Free London NHS Foundation Trust (GB), Manchester Academic Health Science Centre (GB), Western General Hospital (GB), The Francis Crick Institute (GB), University of Surrey (GB), National Institute for Health and Care Research (GB), Manchester University NHS Foundation Trust (GB), Parkinson's UK (GB), King's College Hospital NHS Foundation Trust (GB), National Institute on Aging (US), Oxford University Hospitals NHS Trust (GB), University College London (GB), University of Plymouth (GB)
Funders
Cure Parkinson's Trust, Medical Research Council, Efficacy and Mechanism Evaluation Programme